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In the plasma kallikrein-kinin system, it has been shown that when plasma prekallikrein (PK) and high
molecular weight kininogen (HK) assemble on endothelial cells, plasma kallikrein (huPK) becomes
available to cleave HK, releasing bradykinin, a potent mediator of the inﬂammatory response. Because
the formation of soluble glycosaminoglycans occurs concomitantly during the inﬂammatory processes,
the effect of these polysaccharides on the interaction of HK on the cell surface or extracellular matrix
(ECM) of two endothelial cell lines (ECV304 and RAEC) was investigated. In the presence of Znþ2, HK
binding to the surface or ECM of RAEC was abolished by heparin; reduced by heparan sulfate, keratan
sulfate, chondroitin 4-sulfate or dermatan sulfate; and not affected by chondroitin 6-sulfate. By contrast,
only heparin reduced HK binding to the ECV304 cell surface or ECM. Using heparin-correlated molecules
such as low molecular weight dextran sulfate, low molecular weight heparin and N-desulfated heparin,
we suggest that these effects were mainly dependent on the charge density and on the N-sulfated
glucosamine present in heparin. Surprisingly, PK binding to cell- or ECM-bound-HK and PK activation
was not modiﬁed by heparin. However, the hydrolysis of HK by huPK, releasing BK in the ﬂuid phase, was
augmented by this glycosaminoglycan in the presence of Zn2þ. Thus, a functional dichotomy exists in
which soluble glycosaminoglycans may possibly either increase or decrease the formation of BK. In
conclusion, glycosaminoglycans that accumulated in inﬂammatory ﬂuids or used as a therapeutic drug
(e.g., heparin) could act as pro- or anti-inﬂammatory mediators depending on different factors within the
cell environment.
 2011 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
The plasma kallikrein-kinin system is one of the pathways
responsible for bradykinin (BK) release. Since its discovery, it has
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nder the Elsevier OA license.of inﬂammation (heat, redness, swelling and pain) when injected
into human or animal tissues [1]. In this system, when plasma
prekallikrein (PK) and high molecular weight kininogen (HK)
assemble on endothelial cells in a Znþ2-dependentmanner [2,3], PK
is activated and plasma kallikrein (huPK) is formed, which results in
BK liberation from HK, NO formation [4] and factor XII (FXII) acti-
vation [5].
A primary event of plasma kallikrein-kinin system activation is
HK docking to the cell surface. This binding has been described on
endothelial cells [2e4,6], neutrophils [7], platelets [8], astrocytes
[9], vascular smooth muscle cells [10] and macrophages [11]. Just
out of interest, plasma kallikrein-kinin system activation (including
HK binding) has also been described in a range of epithelial cells
(e.g., lung, gut and prostate epithelium) [12]. On the endothelial cell
surface, some proteins have been found to contain HK binding sites;
these include urokinase plasminogen activator receptor (uPAR),
cytokeratin 1 and receptor for the globular heads of complement
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assays, Schousboe and Nystrøm [14] described the binding of HK to
laminin, a basement membrane protein. Proteoglycans, comprising
a protein core covalently attached to glycosaminoglycans, have also
been suggested as an alternative HK binding site on endothelial
cells [15,16].
Previous studies show that these cell surface proteoglycans are
able to immobilize and regulate the turnover of ligands, protecting
them from proteolytic and chemical inactivation [17] or resulting in
their internalization into endosomes, as shown in experiments
with HK [16]. In addition, the extracellular domains of these
proteoglycans can be shed from the cell surface, generating soluble
glycosaminoglycans that can modulate interactions at the cell
surface.
During inﬂammatory processes, several events occur concomi-
tantly with plasma kallikrein-kinin system activation, such as the
release of heparin from mastocytes, chondroitin 4-sulfate from
platelets [18,19] and heparan sulfate from endothelial cells [20].
These glycosaminoglycans can interact with plasma kallikrein-
kinin system proteins, modulating the inﬂammatory response. In
this regard, heparin and heparin-like molecules have been
considered to hold potential in the treatment of inﬂammatory
diseases [21].
In our previous results, dermatan sulfate and chondroitin sulfate
decreased HK hydrolysis by huPK in vitro, and dermatan sulfate
reduced the rat paw edema induced by carrageenin [22]. Addi-
tionally, the proteolytic activity on other substrates and inhibition
of huPK were differentially modulated by glycosaminoglycans
[23,24]. In the present study, we investigated the effect of glycos-
aminoglycans on the interaction of HK on endothelial cell surfaces
and their extracellular matrix (ECM). Our results suggest that the
interaction of HK on endothelial cells with soluble glycosamino-
glycans is dependent on their structural features. This interaction is
particularly signiﬁcant for heparin, which abolished HK binding,
the initiating step for BK release.
2. Materials and methods
The rabbit aorta endothelial cell (RAEC) linewas kindly provided
by Dr. Vincenzo Buonassisi from the Department of Biology,
University of California, San Diego, CA, USA. The endothelial cell
vein (ECV304) line was obtained from American Type Culture
Collection-ATCC (Manassas, VA, USA). PK and HK were purchased
from EMD Biosciences (San Diego, CA, USA). Bovine lung heparin
(9.5e12 kDa) was obtained from Opocrin Research Laboratory
(Italy), and shark chondroitin 6-sulfate (40e60 kDa) and bovine
intestinal dermatan sulfate (22 kDa) were obtained from Seikagaku
Kogyo Co. (Tokyo, Japan). Bovine chondroitin 4-sulfate (27 kDa),
low molecular weight dextran sulfate (8.0 kDa) and bovine serum
albumin (BSA) were purchased from SigmaeAldrich (St. Louis, MO,
USA), and low molecular weight heparin (Fraxiparin, 5.6e6.4 kDa)
was purchased from Sanoﬁ-Synthelabo Grape (Paris, France).
N-desulfated heparin (6.0 kDa) [25], bovine cartilage keratan
sulfate [26], bovine lung heparan sulfate (30e40 kDa) and tuna
dermatan sulfate (15 kDa) [27] were puriﬁed in our laboratory.
Ham’s F-12 nutrient mixture medium, penicillin and streptomycin
were purchased from Invitrogen (Carlsbad, CA, USA), and fetal calf
serum was purchased from Cultilab (Campinas, SP, Brazil).
The biotinylation kit [NHS-LC-biotin, 2-(40-hydroxyazobenzene)
benzoic acid (HABA) and avidin], ImmunoPure streptavidin
horseradish peroxidase conjugate (SA-HRP) and peroxidase-
speciﬁc fast-reacting substrate, turbo-3,30,5,50-tetramethylbenzi-
dine dihydrochloride (Turbo-TMB) were obtained from Pierce
(Rockford, IL, USA). H-D-Pro-Phe-Arg-pNan (S2302) was purchased
from Chromogenix Instrumentation Laboratory (Milan, Italy).2.1. Biotinylation of puriﬁed proteins
HK and PK were biotinylated as previously described [2,28]. The
protein concentration in each fraction was determined by its
absorbance at 280 nm using the E1% 7.01 for HK and 11.7 for PK [29].
Lyophilized HK or PK was mixed with a 5-fold molar excess of NHS-
LC-biotin (biotin) in 0.10 M phosphate buffer, pH 7.2 for 30 min at
room temperature. The reaction mixture was transferred into
a desalting column PD-10 (GE Healthcare Biosciences, Piscataway,
NJ, USA) equilibrated with 10 mM phosphate buffer, pH 7.2 con-
taining 0.15 M NaCl. Biotin incorporation into HK or PK was
determined by addition of HABA, according to the manufacturer’s
instructions. Both biotin-HK (bHK) and biotin-PK (bPK) migrated as
single chain proteins under reducing conditions (SDS-PAGE).
2.2. Endothelial cell culture
ECV304 is a cell line established from primary culture of human
umbilical vein endothelial cells (HUVEC) [30,31] and has been
described as a derivative of the bladder carcinoma cell line T24 [32].
RAEC is an established endothelial cell line derived from rabbit
aorta [33]. The clones used in this work were positive for endo-
thelial cell markers.
The cells were subcultured in Ham’s F-12 nutrient mixture
medium supplemented with 10% heat-inactivated fetal calf serum,
10 U penicillin and 10 mg/mL streptomycin and grown to conﬂuence
in 60 mm dishes. For binding experiments, cells were seeded at
2.0  104 cells/well and grown to conﬂuency for 24 h (ECV304) or
48 h (RAEC) at 37 C in 2.5% CO2.
2.3. Preparation of extracellular matrix
ECM obtained from either ECV304 or RAEC were prepared fresh
prior to the start of each experiment [34]. Brieﬂy, cells were sub-
cultured on microtiter plate wells and removed by treatment with
0.5% Triton X-100 (p/v) in 10 mM phosphate buffer, pH 7.4 con-
taining 0.15 M NaCl for 15 min (37 C, 2.5% CO2). Next, cells were
incubated with 25 mMNH4OH for 10 min at 37 C and thenwashed
extensively with 20 mM tris(hydroxymethyl)aminomethane (Tris)
buffer, pH 7.4 containing 0.15 M NaCl and 0.05% Tween-20 (p/v).
Subsequently, no cells in the microtiter plate were detected by light
microscopy. The adherent subendothelial matrix reacted with
antibodies to ﬁbronectin and perlecan (data not shown).
2.4. Binding of biotinylated proteins
Considering the experiments performed with ECV304 cell
surfaces or ECM, all incubations and washes were performed in N-
(2-hydroxyethyl)-piperazine-N0-2-ethanesulfonic acid (HEPES)-
Tyrode’s binding buffer (15 mM HEPES, 0.14 M NaCl, 2.7 mM KCl,
12 mM NaHCO3, 0.36 mM NaH2PO4), pH 7.4 containing 3.5 mg/mL
dextrose, 50 mM ZnCl2, 1.0 mMMgCl2, 2.0 mM CaCl2 and 0.35% BSA
as protein carrier [3]. For experiments performed with RAEC
surfaces or ECM, the binding buffer was HEPES-carbonate (5.0 mM
HEPES, 0.15 M NaCl, 5.6 mM KCl, 3.6 mM NaHCO3), pH 7.4 con-
taining 1.0 mg/mL dextrose, 25 mM ZnCl2, 1.0 mM MgCl2, 2.0 mM
CaCl2 and 0.10% gelatin as a protein carrier [4,16].
The cell surface or ECM from both cell lines was washed ﬁve
times with the respective binding buffer before performing all
binding studies. After, they were incubated with 20 nM bHK in the
absence or presence of 1.0 mM glycosaminoglycans for 1 h at 37 C
in a 100 mL-reaction volume. The unbound bHK was then removed
by washing three times with the binding buffer.
Cell or ECM-associated bHK was measured by incubation with
SA-HRP (2.0 mg/mL) in a ﬁnal volume of 100 mL for 1 h at room
Fig. 1. Inﬂuence of glycosaminoglycans on HK binding to endothelial cells. bHK
(20 nM) was bound to RAEC (A) or ECV304 (B) cells and their ECM in appropriate
buffer for 1 h at 37 C in the absence or presence of glycosaminoglycans: heparin
(Hep), heparan sulfate (HS), tuna dermatan sulfate (TDS), bovine dermatan sulfate
(BDS), keratan sulfate (KS), chondroitin 4-sulfate (C4S) or chondroitin 6-sulfate (C6S),
at a ﬁnal concentration of 1.0 mM. The ﬁgures show the mean  SD of two different
experiments performed in triplicate. *r < 0.01 versus bHK.
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as previously reported [28]. Bound bHK was quantiﬁed by
measuring the absorbance at 450 nm. The bHK binding was
calculated by subtracting bound bHK in the presence of Znþ2 from
bHK in the absence of Znþ2, and the data were expressed as
a percentage with the bHK binding in absence of glycosaminogly-
cans set as 100%.
Bound bPK was measured on conﬂuent monolayers of RAEC and
ECV304 cells and ECM. Brieﬂy, after ﬁvewashes with the respective
binding buffers, cells or ECM were incubated with 20 nM HK
(100 mL) for 1 h at 37 C. Unbound HK was removed by aspiration,
and after three washes with binding buffer, 20 nM bPK was added
in the absence or presence of 1.0 mM heparin for 1 h at 37 C in
a 100 mL-reaction volume. Cell or ECM-associated bPK was detected
using SA-HRP and the substrate turbo-TMB as described previously
for bHK. The bPK binding was calculated by subtracting bound bPK
in the presence of HK from bPK bound in the absence of HK, and the
data were expressed as a percentage.
2.5. PK activation on endothelial cells and their ECM
in the presence of heparin
Conﬂuent monolayers of RAEC and ECV304 cells or their matrix
were washed ﬁve times with the respective binding buffer. After,
cells or ECMwere incubatedwith 20 nMHK (100 mL) for 1 h at 37 C.
Unbound HK was removed by aspiration, and after three washes
with binding buffer, 20 nM PK (100 mL) was added in the absence or
presence of 1.0 mMheparin for 1 h at 37 C. After this incubation, the
unbound PK was removed by aspiration and the plate was washed
three timeswith 0.10mMphosphate buffer, pH 7.4with 0.14MNaCl.
Kallikrein activity was measured with the hydrolysis of 0.4 mM H-
D-Pro-Phe-Arg-pNan for 2 h at 37 C at 405 nm [3,4].
2.6. HK hydrolysis by huPK in the presence of Znþ2 and heparin
The Znþ2 is an essential cofactor for assembly and activation of
contact system proteins bound to endothelial cells [5]. The inﬂu-
ence of these ions and heparin on HK hydrolysis by huPK and BK
release was investigated.
HK (6.0 mM) was incubated with or without heparin (0.26 mM)
and 50 mM ZnCl2 in 50 mM Tris buffer, pH 8.0 containing 0.15 M
NaCl for 5 min at 37 C, and then huPK (5.2 nM) was added in a ﬁnal
volume of 20 mL. Aliquots were removed at various times up to
15 min, and BK was extracted in ethanol for 10 min at 70 C and
quantiﬁed by radioimmunoassay as described by Shimamoto et al.
[35] with some modiﬁcations [22].
2.7. Statistical analysis
The results are shown as the mean  SD of two different
experiments performed in triplicate. Statistical analyses were per-
formed using the commercial program GraphPad Prism Version 5
(GraphPad Software Inc, San Diego, CA, USA). One way analysis of
variance with Dunnet post test was used.
3. Results
3.1. Effect of glycosaminoglycans on HK binding to endothelial cells
Previous studies have characterized HK binding in a Znþ2-
dependent manner with both ECV304 [3] and RAEC [16, MSc. A.
Gutierrez, personal communication]. Here, we investigated the
binding of HK and PK on HK bound to these cells in the presence of
soluble glycosaminoglycans: heparin, heparan sulfate, dermatan
sulfate, chondroitin sulfate and keratan sulfate.To verify if the nature of the glycosaminoglycan could affect HK
binding on the cell surface, two distinct cell types with different
glycosaminoglycan content were used: RAEC, which presents 20%
chondroitin sulfate and 80% heparan sulfate with typical heparin
sequences, and ECV304 with 50% of each glycosaminoglycan
[36,37].
First, experiments were performed to determine whether HK
binding to RAEC or ECV304 cell surfaces and their matrix was
inﬂuenced by different glycosaminoglycans. On both the RAEC
surface and ECM, almost all of the glycosaminoglycans decreased
HK binding compared to the control. On the RAEC surface (Fig. 1A),
bHK binding was abolished in the presence of heparin, but bHK
binding decreased to 57%, 61%, 68% and 75% in the presence of
heparan sulfate, chondroitin 4-sulfate, tuna and bovine dermatan
sulfates, respectively. On RAECmatrix (Fig.1A), glycosaminoglycans
had the same effect: decreasing bHK binding. The bHK binding to
RAEC surface and their matrix was abolished in the presence of
heparin and decreased to 57%, 65%, 70%, 69% and 80% with heparan
sulfate, chondroitin 4-sulfate, tuna and bovine dermatan sulfates
and keratan sulfate, respectively. However, binding was not
affected by chondroitin 6-sulfate.
The bHK binding to the ECV304 cell surface and ECM was
decreased by approximately 50% by heparin. On the cell surface,
keratan and chondroitin 6-sulfate caused a discrete increase in this
binding (Fig. 1B).
The results showed that in both RAEC and ECV304 cell lines,
heparin was the glycosaminoglycan that had the most signiﬁcant
effect on disturbing HK binding to endothelial cell surface or
matrix.
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Based on the effects of heparin on HK binding to either RAEC
and ECV304 cell surfaces or their ECM, its role in binding was
further examined.
The bHK binding was analyzed in the presence of different
heparin concentrations. Biotin-HK binding to RAEC surfaces and
their ECM was completely abolished in the presence of 0.50 mM
heparin (Fig. 2A). However, on ECV304 cell surfaces and their ECM,
concentrations higher than 50 mM heparin were necessary to
abolish bHK binding (Fig. 2B).
To determine if the effect of heparin could be related to its size
or charge, heparin-like species such as low molecular weight
heparin, N-desulfated heparin and low molecular weight dextran
sulfate were tested. Biotin-HK binding to RAEC surfaces and their
ECM was completely abolished in the presence of heparin and low
molecular weight dextran sulfate, but this binding was reduced to
15e20% in the presence of low molecular weight heparin and was
not affected in the presence of N-desulfated heparin (Fig. 3A). By
contrast, on ECV304 cell surfaces or ECM, the binding was almost
abolished in the presence of low molecular weight dextran sulfate,
reduced to 50% with heparin, reduced to 55e60% with low
molecular weight heparin and was unaffected by N-desulfated
heparin (Fig. 3B). These data suggest that the sulfate content on
glycosaminoglycans is essential for its inﬂuence on HK binding to
cell surfaces and ECM of these cell lineages.Fig. 2. Effect of heparin on HK binding to endothelial cells. RAEC (A) or ECV304
(B) cells and their ECM were incubated with bHK (20 nM) in the absence or presence
of heparin (1.0 nMe50 mM) in appropriate buffer for 1 h at 37 C. The ﬁgures show
the mean  SD of two different experiments performed in triplicate. *r < 0.01,
**r < 0.05.
Fig. 3. Inﬂuence of different heparins and dextran sulfate on HK binding to endothelial
cells. bHK (20 nM) was bound to RAEC (A) or ECV304 (B) cells and their ECM in
appropriate buffer for 1 h at 37 C, in the absence or presence of heparin (Hep), low
molecular weight heparin (LMWHep), N-desulfated heparin (N-des Hep) or low
molecular weight dextran sulfate (LMWDXS), at a ﬁnal concentration of 1.0 mM. The
ﬁgures show the mean  SD of two different experiments performed in triplicate.
*r < 0.01 versus bHK.3.3. Effect of heparin on PK binding and activation
HK is a putative receptor for PK on endothelial cells, and it was
observed that heparinmodiﬁed HK interactionwith the endothelial
cell surface and ECM. Therefore, the effect of this glycosamino-
glycan on the interaction between HK and PK was investigated.
First, HKwas incubatedwith endothelial cells or ECM, and then bPK
with or without heparin was added (Fig. 4). Because the activation
of PK on endothelial cells and ECM was previously characterized
[3,4], the effect of heparin on PK activation was also investigated
(Fig. 5). The results in Figs. 4 and 5 show that heparin did not have
any effect on bPK binding to HK or on activation of PK in these cell
lineages. In this context, this glycosaminoglycan interferes with the
plasma kallikrein-kinin system by speciﬁcally interacting with HK,
not with PK or huPK formed on the cell surface or ECM.
3.4. Effect of heparin and Znþ2 on HK hydrolysis
Despite the fact that formation of huPK on the cell surface or
ECM was not modiﬁed by heparin, the inﬂuence of this glycos-
aminoglycan and Znþ2 on HK hydrolysis by huPK was performed
in vitro. BK release in the presence or absence of heparin and/or
Znþ2 was quantiﬁed by radioimmunoassay. When HK was pre-
incubated with Znþ2, the rate of BK release was signiﬁcantly
higher than in the absence of this cation (Fig. 6). Without Znþ2,
heparin did not signiﬁcantly affect the rate of BK formation. In the
presence of the cation, heparin increased BK release when
compared to the control without Znþ2, but when compared to the
control with Znþ2, this effect only appeared with low concentra-
tions of HK (Fig. 6). These results indicated the importance of Znþ2
within the cell environment, the presence of which enhances the
Fig. 4. Effect of heparin on bPK binding to HK. RAEC (A) or ECV304 cells (B) and their
ECM were ﬁrst incubated with HK (20 nM). After washing to remove the unbound HK,
bPK (20 nM) was added in the absence or presence of heparin (Hep), at a ﬁnal
concentration of 1.0 mM for 1 h at 37 C. The ﬁgures show the mean  SD of two
different experiments performed in triplicate.
Fig. 6. Effect of heparin and Znþ2 on HK hydrolysis by huPK. Human plasma kallikrein
(5.2 nM) in 50 mM Tris buffer, pH 8.0 containing 0.15 M NaCl was incubated with HK
(0.50e6.0 mM) in the presence or absence of ZnCl2 (50 mM) and/or heparin (Hep-
260 nM). Five microliter aliquots were removed at various times (0e15 min), and BK
release was quantiﬁed by radioimmunoassay. The ﬁgure shows the mean  SD of two
different experiments performed in triplicate. *r < 0.01 versus huPK þ HK, **r < 0.01
versus huPK þ (HK þ Znþ2).
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this cation in the inﬂammation site depends on activated platelets,
which release high amounts of Znþ2 and interact with endothelial
cells to contribute to the inﬂammatory processes [38].Fig. 5. Effect of heparin on PK activation. RAEC (A) or ECV304 cells (B) and their ECM
were ﬁrst incubated with HK (20 nM). After washing to remove the unbound HK, PK
(20 nM) was added in the absence or presence of heparin (Hep), at a ﬁnal concentration
of 1.0 mM for 1 h at 37 C. After washing to remove the unbound PK, H-D-Pro-Phe-Arg-
pNan (0.4 mM) was added. The rate of hydrolysis was measured for 2 h at 37 C. The
ﬁgures show the mean  SD of two different experiments performed in triplicate.4. Discussion
Recent studies in glycobiology have shown that glycosamino-
glycans and their related proteoglycans participate in a variety of
cell communication events and are able to initiate and control
processes associated with inﬂammation [39,40]. During inﬂamma-
tory processes, free glycosaminoglycans serve as a molecular signal
of injury. Higher levels of speciﬁc glycosaminoglycans and their
low molecular weight fragments released by glycosaminoglycan-
digesting enzymes have been observed in patients with osteoar-
thritis, rheumatoid arthritis, psoriasis, scleroderma and inﬂamma-
tory bowel disease and may adversely inﬂuence the course of these
disorders [41]. In this scenario, these released polysaccharides can
interact with circulating proteins, such as plasma kallikrein-kinin
system components, modulating bradykinin generation in the
inﬂammation site.
BK release in the endothelial cell environment depends on the
assembly of HK-PK complex in an ordered manner. It is already
known that HK attaches to the endothelial cell surface by docking
to the uPAR, gC1qR, cytokeratin 1 [13], heparan sulfate and chon-
droitin sulfate chains of cellular proteoglycans [15,42]. PK binds to
cell-bound HK through its heavy chain and becomes activated;
subsequently, huPK cleaves HK, releasing BK.
In the present work, we demonstrated that HK binding to RAEC
and ECV304 was decreased or abolished, respectively, in the pres-
ence of soluble heparin. Other glycosaminoglycans studied in this
work had amore slight inﬂuence in this binding, showing that there
is speciﬁcity in the observed effect beyond a purely electrostatic
action. Corroborating this fact, chondroitin sulfate and dermatan
sulfate (three times longer than heparin) were less efﬁcacious in
affecting HK binding. Additionally, using heparin-correlated mole-
cules such as low molecular weight dextran sulfate, low molecular
weight heparin and N-desulfated heparin, we conﬁrmed that the
size of the glycosaminoglycan is less important for the effect on HK
binding than its charge density and the N-sulfated glucosamine
content. The importance of sulfate contentwas previously shownby
Linhardt et al. [43], which described a relationship between high
sulfate content of glycosaminoglycans and the enhancement of their
anticoagulant and antithrombotic activities.
The decrease of this interaction with the cell surface or ECM by
the addition of soluble glycosaminoglycans can be explained by the
disruption of HK docking to cellular proteoglycans in a competitive
manner. Similar results were previously obtained for the binding of
chemokines to HUVEC, which can be affected by soluble glycos-
aminoglycans such as heparin in a competitive manner [44].
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The effect of heparin on the reduction of HK binding to RAEC
was more prominent in comparison to ECV304 (100-fold more
heparin was necessary to abolish HK binding). Considering that HK
binds to the endothelium through cellular proteoglycans, the
content and composition of these molecules in each cell type
[36,37] may be an important factor. Another remarkable fact is that
ECV304 has 2.5-times more binding sites (including proteins and
proteoglycans) for HK than RAEC (unpublished data from MSc. A.
Gutierrez). Together, these considerations might explain the
smaller effect of heparin on ECV304 as compared to RAEC. Different
patterns of glycosaminoglycan expression on cells may favor the
binding of certain proteins and thereby inﬂuence the cellular
composition in the inﬂammatory response [44,46].
The possibility that HK binds heparin has been attributed to its
molecular structure composed of different well-characterized
domains. In this respect, the ﬁfth domain of HK is a histidine-
glycine-rich region (amino acids 384e502), which confers to this
domain the ability to bind to anionic surfaces such as heparin in the
presence of Znþ2 [47]. Similar binding properties were found for
bHK and heparin in the presence of Znþ2 (data not shown), indi-
cating that the biotinylation process did not affect HK capacity to
bind to anionic surfaces. The interaction between HK and heparin
in the presence of Znþ2 modiﬁes HK binding to the endothelial cell
surface or ECM. However, the structure of HK is notmodiﬁed by this
interaction, as veriﬁed by circular dichroism and ﬂuorescence
spectroscopy (data not shown).
Considering the activation of plasma kallikrein-kinin system on
endothelial cells, our results show that if HK is already bound, PK
docking to the cell-adsorbed HK and PK activation are not affected by
heparin.However, Rennéet al. [17] suggested that glycosaminoglycan-
degrading enzymes detach HK from cell proteoglycans, promoting BK
formation initiated by FXII activation. Our results seem to be different
from the results shown by those authors [17]. However, here the
assembly of the HKePK complex on cellular surfaces occurs in the
absenceof FXIIa, andPK is activatedbyprolylcarboxypeptidase [48,49]
or heat shock protein 90 [50].
Besides the effect of glycosaminoglycans on HK, which inter-
feres with plasma kallikrein-kinin system activation on endothelial
cells, it has been reported that these molecules can affect the action
and inhibition of huPK. In this context, in vitro experiments
revealed that heparin enhances huPK inhibition by antithrombin
[24,51] and C1-inhibitor [24]. It was also shown that heparin
interferes with huPK activity on FXII, plasminogen and synthetic
substrates [23,24] and that it slightly modiﬁes the hydrolysis of HK
by huPK [22]. Here, we show that in the presence of Znþ2, heparin,
at a therapeutic concentration, increased BK release. Other authors
have shown that heparin added to plasma induces BK release by
activation of FXII [45] and that heparan sulfate and chondroitin
sulfate do not induce BK formation [17].
The fact that glycosaminoglycans interfere or augment the
formation of BK can have important implications when they are
used as therapeutic drugs. The contamination of heparinwith over-
sulfated chondroitin sulfate causes adverse reactions in patients,
mainly in the form of refractory hypotension, solely in response to
the high production of BK [52]. Therefore, new investigations will
be necessary to understand the biological consequences of these
interactions.
These results raise the possibility of a functional dichotomy in
which soluble glycosaminoglycans either interfere or augment the
formation of BK generated by plasma kallikrein-kinin system acti-
vation. The effect of glycosaminoglycans in terms of BK release
likely depends on various factors within the cell environment,
namely the availability of Znþ2, the soluble glycosaminoglycansformed, the kallikrein inhibitors and the activation of PK, among
others. Together, these factors can interfere with plasma kallikrein-
kinin system proteins, thereby modulating BK release and, subse-
quently, the regulation of inﬂammatory processes.5. Conclusion
In this work, the effect of glycosaminoglycans on the interaction
of HK on the cell surface or ECM of endothelial cells was examined.
Using a combination of binding, kinetic and conformational assays,
we showed that heparin reduced or abolished HK binding to the
endothelial cell surface or ECM. This HK binding is the initiating
step for BK release, a potent mediator of the inﬂammatory
response. However, if HK is attached to the endothelial surface or
ECM, heparin does not exert any effect on PK binding or activation.
However, if huPK is available in the presence of Znþ2, an increase in
BK liberation is observed, which may contribute to inﬂammatory
processes. The obtained results provide both new information on
the relationship between the plasma kallikrein-kinin system and
glycosaminoglycans and novel insights into the regulation of local
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